Small Business Innovation Research on Rare Musculoskeletal, Rheumatic and Skin Diseases (R43)

The summary for the Small Business Innovation Research on Rare Musculoskeletal, Rheumatic and Skin Diseases (R43) Federal Grant is detailed below. It contains information such as the Catalog of Federal Domestic Assistance (CFDA) number, who is eligible for the grant, how much grant money will be awarded, important deadlines, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed in the Grant Announcement Contact section. If these sections are incomplete, please visit the website of the government agency that is offering this grant.

	Federal Grant Title:	Small Business Innovation Research on Rare Musculoskeletal, Rheumatic and Skin Diseases (R43)
	CFDA Number:	93.846
	CFDA Description:	Arthritis, Musculoskeletal and Skin Diseases Research
	Federal Agency Name:	National Institutes of Health
	Category of Funding Activity:	Health
	Category Explanation:	Information not provided
	Opportunity Category:	Discretionary
	Funding Opportunity Number:	RFA-AR-12-006
	Document Type:	Grants Notice
	Funding Instrument Type:	Grant
	Posted Date:	Jun 10, 2011
	Creation Date:	Jun 10, 2011
	Original Closing Date for Applications:	Oct 11, 2011
	Current Closing Date for Applications:	Oct 11, 2011
	Archive Date:	Nov 11, 2011
	Expected Number of Awards:	Information not provided
	Estimated Total Program Funding:	1,500,000
	Federal Grant Award Ceiling:	300,000
	Federal Grant Award Floor:	Information not provided
	Cost Sharing or Matching Requirement:	No

Applicants Eligible for this Grant

Small businesses

Additional Information on Eligibility

Information not provided

Grant Description

This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose preclinical studies to advance the development of biomarkers or treatments for rare musculoskeletal, rheumatic or skin diseases. Rare diseases have a prevalence of fewer than 200,000 affected individuals in the United States. Also eligible for potential funding through this initiative are studies of FDA-designated orphan products for musculoskeletal, rheumatic or skin diseases. See the NIAMS Long-Range Plan for more information about NIAMS research interests (http://www.niams.nih.gov/About_Us/Mission_and_Purpose/long_range.asp).

Link to Full Grant Announcement

http://grants.nih.gov/grants/guide/rfa-files/rfa-ar-12-006.html

Grant Announcement Contact

NIH OER WebmasterFBOWebmaster@OD.NIH.GOV
If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [FBOWebmaster@OD.NIH.GOV]

Similar Government Grants

• NIAMS Clinical Trial Implementation Cooperative Agreement (U01)

• Support of NIAMS Program Project Grants (P01)

• Multidisciplinary Clinical Research Centers (P60)

• NIAMS Multi-Center Clinical Study Implementation Planning Grants (U34)

• NIAMS Clinical Study Implementation Cooperative Agreement (UM1)

• COLLABORATIVE ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES SCIENCE AWARD (CAMSSA)

• NIAMS SMALL GRANT PROGRAM FOR NEW INVESTIGATORS

• SKIN DISEASES RESEARCH CORE CENTERS

• CORE CENTERS FOR MUSULOSKELETAL DISORDERS

• MICROCIRCULATION AND TARGET ORGAN DAMAGE IN RHEUMATIC AND SKIN DISEASES